Quantum BioPharma (NASDAQ: QNTM) shareholders approved a series of resolutions at the company's annual general and special meeting on Nov. 10, 2026, including authorization to issue additional Class A multiple voting shares to maintain up to 70% aggregate voting power, a 2026 omnibus equity incentive plan, a potential share consolidation at a ratio of up to 10-for-1 and a potential corporate name change, according to NEWMEDIAWIRE. The board retains discretion over whether and when to implement the authorized measures.
The company also closed a non-brokered private placement of 26 Class A multiple voting shares on Nov. 9 at C$3.11 per share, generating gross proceeds of C$80.86. Xorax Family Trust, associated with CEO Zeeshan Saeed, and Fortius Research and Trading Corp., controlled by director Anthony Durkacz, each acquired 13 shares. Following the placement, the aggregate voting power of Class A multiple voting shares increased from approximately 57.01% to 68.22%.
The transaction was completed under shareholder authorization granted in 2025, with proceeds designated for general working capital purposes. The company also reappointed MNP LLP as auditor and elected all five director nominees. For a detailed account of the meeting outcomes and the placement, the full press release is available at https://ibn.fm/UagXR.
The sharp increase in insider voting control is significant for public investors because it concentrates decision-making power in the hands of management and a director. With Class A multiple voting shares now representing 68.22% of aggregate voting power, insiders can exert substantial influence over matters submitted to shareholders, including the election of directors and approvals of equity plans. The authorization to issue additional Class A multiple voting shares to maintain up to 70% aggregate voting power further entrenches that influence, potentially limiting the sway of ordinary shareholders.
The approved 2026 omnibus equity incentive plan and the potential share consolidation at a ratio of up to 10-for-1 also carry implications for current holders. A consolidation would reduce the number of outstanding shares and could affect the company's share price and liquidity, though the board has not committed to implementing it. Similarly, the potential corporate name change, if pursued, would not alter the company's legal structure but could signal a strategic repositioning.
Quantum BioPharma is a biopharmaceutical company focused on treatments for neurodegenerative and metabolic disorders and alcohol misuse. Its lead compound, Lucid-MS, is a patented new chemical entity shown in preclinical models to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis. The company also invented UNBUZZD and retains a 19.84% ownership stake in Unbuzzd Wellness Inc. as of March 31, 2026, along with royalty payments of 7% of sales until payments total $250 million, after which the royalty drops to 3% in perpetuity.
For ongoing updates on Quantum BioPharma, the company maintains a newsroom at https://ibn.fm/QNTM. Terms of use and disclaimers applicable to content provided by IBN are available at https://IBN.ai/Disclaimer. The company notes that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied.
